The reintroduction of poison gas in warfare by the Germans in 1915 stimulated experimental studies, both in the clinic and in the animal laboratory, on the effect of these agents upon various body 
suggested that one of the derivatives had potentialities for effective therapeutic use in malignant disease. Owing to security restrictions imposed by the war, the results of these latter studies were In twelve instances there was no change in the red blood count. In the remaining eight there was a drop of about one million cells which took place from the second day to the second week after the beginning of treatment.
A sharp reduction in the number of lymphocytes was observed eleven times (in 3 of these the count went down to 0); in five instances the reduction was moderate; and in four it was negligible. The reduction occurred within a day or two after the first injection and the maximum drop was usually observed before the course of treatment had been completed. The return to normal occurred in about two weeks.
Concomitant with the fall in lymphocytes there was often a relative increase in the number of granulocytes. After two to three weeks a definite granulocytopenia developed in 9 cases. This was severe (below 20 per cent) in 4 and moderate (20 to 45 per cent) in 5 others. In 10 instances there was no secondary granulocytopenia. One patient died too soon after treatment for any change to occur. A severe leukopenia (below 1000 cells per cubic millimeter of blood) occurred five times and a moderate leukopenia (1000 to 2000 cells) 8 times.
A drop in the total white count to levels between 2000 and 4000 was recorded five times. In one instance death occurred too soon for evaluation, and in another there was no change in the count. The leukopenia was usually observed at the same time that the granulocytopenia developed. Patients with severe leukopenia and granulocytopenia were treated with frequent transfusions of blood and with penicillin. The total white count and the granulocyte count returned to normal after two to three weeks. During the period of agranulocytosis one patient developed an abscess in a pilonidal cyst, another had ulcerative tonsillitis and a paronychia, and in a third there was an aggravation of an existing infected scalp and osteomyelitis of the skull. All three patients recovered from the infections.
An alarming thrombocytopenia developed six times. The drop in the platelet count was observed from six days to four weeks after the first injection. Four patients in this group exhibited moderate to severe purpuric manifestations, one had a profuse menstrual flow, and one had no demonstrable hemorrhagic changes. The thrombocytopenia was successfully combated by frequent transfusions of blood.
Administration of the drug did not appear in any consistent manner to initiate or to aggravate any abnormalities in blood chemistry. In all the earlier cases determinations were made of total protein, albumin, globulin, non-protein nitrogen, total and free cholesterol, amino acid nitrogen, icterus index, and cephalin flocculation.
Results of treatment Hodgkin's disease (6 cases). In all 6 patients an appreciable diminution in the size of the dispersed lesions was detected by x-ray and physical examination shortly after the administration of the drug. Maximum regression occurred 10 to 14 days after treatment. Although the regression was occasionally very dramatic, in no case was there a complete, even if only temporary, disappearance of the disease. Four patients in this group of six have already died, the survival period varying from five to twenty-four months after the onset of the disease, and from two to eleven months after treatment with nitrogen mustard. The periods of remission varied from less than two months to six months. Two patients are still alive, 13 and 22 months, respectively, after the onset of the disease. One of these, a woman of 34 years, has had two courses of treatment with the drug. A remission period of only one and one-half months followed the first course. Because of severe involvement of the cervical lymph nodes which threatened momentary respiratory obstruction, the second course was combined with x-ray therapy. The immediate response was only moderate, but not enough time has elapsed for proper evaluation. In the second living patient, a girl of six, the administration of the drug, at a time when the disease had become resistant to x-ray treatment, was promptly followed by a pronounced regression of all the involved nodes. Today, only three months after treatment there are, however, signs of recurrence.
Lymphocytic lymphoma (1 case; 2 courses of nitrogen mustard treatment). There was diminution in the size of the nodes, lasting only three months. He was given a second course of treatment which resulted in improvement lasting about six months. Because of rapidly increasing bilateral pleural effusions which had necessitated frequent thoracenteses he was given x-ray therapy in the hope of creating a synechia between the visceral and parietal pleural layers. Temporary reduction in the formation of pleural fluid was accomplished, but his course continued progressively down-hill and he died 36 months after the onset of his disease, 22 months after the first course of nitrogen mustard therapy, and 18 months after the second.
Lymphoblastic lymphoma (1 case; 2 courses of nitrogen mustard treatment). No appreciable beneficial effect was produced by the first course but subsequent x-ray therapy resulted in marked improvement which lasted for about six months. A second course of drug treatment, administered one month ago, has resulted thus far in a slight improvement. * Stem-cell lymphoma (2 cases). In the first case no beneficial effect was observed and the patient died 29 months after the onset of the disease and five months after the treatment. The second patient is still alive 8 months after the onset of the disease. The drug, administered 4 months ago, has provided definite symptomatic improvement and the patient, previously bedridden, is now able to get about and to resume some of her household activities.
Mycosis fungoides (1 case). This colored woman of 22 years has had diffuse lesions involving the skin of practically her entire body for the past 7 years. Repeated biopsies have demonstrated a picture typical of mycosis fungoides, but with no evidence of malignant change. Multiple courses of x-ray therapy have succeeded in shrinking some of the lesions and in alleviating only temporarily the severe itching of the skin. A course of nitrogen mustard therapy, administered five months ago, resulted in a very appreciable reduction in the size of all the skin lesions and in a marked improvement, though not in a complete cessation of the itching. These beneficial effects have lasted to date.
Mycosis fungoides with reticulum cell sarcoma (1 case). This patient had a severe reaction from the drug and died two days after completion of the treatment. At autopsy he had diffuse neoplastic involvement in addition to arteriosclerotic heart disease and signs of congestive failure.
Pleomorphic cell sarcoma arising in giant follicle lymphoma (1 case). Roentgenograms taken twenty days after the initial injection of the drug demonstrated an increase in the size of the chest lesions. The patient died 6 years after the onset of the disease and one month after drug treatment.
Embryonal carcinoma of the testis (1 case). An increase in the size of the pulmonary metastases was noted on x-ray examination twenty days after treatment with the drug. The patient was subsequently given stilbestrol which seemed to hold the disease temporarily in check. He died 13 months after the onset of his disease and 12 months after nitrogen mustard therapy.
Fibrosarcoma of chest wall (1 case). This patient, a white male of 45 years, was critically ill with a huge fibrosarcoma that had arisen from the soft tissues of the left posterior chest wall. There were multiple metastases in both lungs. Previous x-ray therapy at another hospital had not been effective. In desperation a course of 4 daily injections of nitrogen mustard was administered but no beneficial result was noted. The patient died five months after the onset of the disease and three weeks after the drug treatment.
Ewing tumor of pelvic bone ( 1 case) . A white lad, 18 years of age, had been treated previously with x-radiation for a large tumor of the pubic bone. Fairly prompt shrinking of the tumor occurred. A second course of radiotherapy was given eight months later when he developed pulmonary metastases. The metastases appeared to increase in size during the course of the radiation therapy and in desperation he was treated with nitrogen mustard. This was followed by a definite symptomatic improvement and by a slight diminution in the size of the pulmonary metastases, as revealed by roentgen examination. The improvement has, however, been only brief and at the present moment, less than two months after treatment with the drug, he is already reporting a recurrence of his former symptoms.
Conclusions
This series is too small to permit any proper statistical analysis. Certain trends may, however, be noted:
( 1 ) The drug was not curative in any of the cases in this group. Ten patients have already died; six are still alive, but are far from cured.
(2) Hodgkin's disease appeared to be most susceptible to the drug. There was an early, often a marked, but always a relatively short-lived reduction in the size of the lesions. With the possible exception of the patient who had become resistant to the x-ray, the improvement was not sufficient to delay death appreciably.
(3) One patient with mycosis fungoides received very substantial benefit from the drug, thus far for a period of about five months; one patient with stem-cell lymphoma is still symptomatically improved four months after treatment; and one patient with Ewing tumor of the pelvic bone was improved for less than two months.
(4) The drug is not innocuous. It has a toxic, depressing effect upon all the blood elements, and not infrequently brings about an alarming degree of agranulocytic leukopenia and of thrombocytopenia.
In summary, it may be stated that the drug has a useful place in the treatment of lymphomatous malignant disease and especially of Hodgkin's disease. Its beneficial effects are similar in kind and often in degree to those resulting from x-ray treatment. It has a particular field of usefulness in patients who have become resistant to radiotherapy. Its value in embryonal types of neoplastic disease outside of the lymphoma group has as yet not been adequately studied. It is likely that it may cause temporary remissions, as it did in the one case of Ewing tumor in this series, but it is doubtful if it will demonstrate any lasting curative properties. In this Clinic, radiotherapy is still the treatment of choice for any of the histological varieties of the lymphomata, provided the disease is localized. The nitrogen mustard drug is reserved for those patients who have diffuse systemic involvement and for those who have become resistant to the x-ray.
